Gilead Sciences vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Antiviral biopharma with $28.6B FY2024 revenue; Biktarvy $14B HIV franchise; lenacapavir 99%+ HIV prevention efficacy in 2024 trials is landmark breakthrough; Trodelvy oncology expansion.
About
Gilead Sciences is a biopharmaceutical company specializing in antiviral medicines, oncology, and inflammatory diseases, founded in 1987 and headquartered in Foster City, California, trading on Nasdaq (GILD). The company reported approximately $28.6 billion in total revenues for FY2024 under CEO Daniel O'Day, driven by the world's leading HIV treatment franchise anchored by Biktarvy—the world's best-selling antiretroviral therapy with over $14 billion in annual global sales—along with Veklury (remdesivir) for COVID-19 treatment, and a growing oncology portfolio including Trodelvy (sacituzumab govitecan, an ADC for breast and bladder cancer), Yescarta, and Tecartus (CAR-T cell therapies). Gilead's 2024 HIV prevention breakthrough—lenacapavir, a twice-yearly injection preventing HIV infection with near-100% efficacy in large clinical trials—represents potentially the most important HIV prevention advance since the development of daily oral PrEP.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.